Head-to-head evidence
Brolucizumab-Dbll vs HLX04-O
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
Brolucizumab-Dbll
Marketed by Novartis
NCT05672979 · Phase 3 · status unknown
This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.
HLX04-O
Developed by Shanghai Henlius Biotech
NCT04740671 · Phase 3 · completed
The trial randomized 410 participants to HLX04-O or the active comparator ranibizumab and masked both participants and investigators. Its primary clinical endpoint was the mean change in best-corrected visual acuity at Week 36, but no statistical comparison or outcome result is available yet.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brolucizumab-Dbll's landscape · HLX04-O's landscape